Gradient Investments LLC Cuts Holdings in Medtronic PLC $MDT

Gradient Investments LLC reduced its stake in Medtronic PLC (NYSE:MDT) by 8.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 452,838 shares of the medical technology company’s stock after selling 43,675 shares during the period. Gradient Investments LLC’s holdings in Medtronic were worth $39,075,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. grew its stake in Medtronic by 0.7% during the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock worth $8,919,846,000 after buying an additional 838,220 shares during the last quarter. State Street Corp boosted its holdings in shares of Medtronic by 2.0% during the fourth quarter. State Street Corp now owns 61,660,158 shares of the medical technology company’s stock valued at $5,966,780,000 after acquiring an additional 1,199,621 shares during the period. Bank of America Corp DE grew its position in shares of Medtronic by 5.4% during the first quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after acquiring an additional 1,343,220 shares during the last quarter. First Eagle Investment Management LLC increased its holdings in shares of Medtronic by 37.2% in the 2nd quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock worth $1,078,321,000 after acquiring an additional 3,739,288 shares during the period. Finally, WCM Investment Management LLC acquired a new stake in shares of Medtronic in the 1st quarter worth about $965,922,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Price Performance

Shares of Medtronic stock traded up $2.29 during trading on Thursday, hitting $87.80. The stock had a trading volume of 48,592,137 shares, compared to its average volume of 10,245,308. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The firm has a market cap of $112.31 billion, a P/E ratio of 21.71, a PEG ratio of 1.98 and a beta of 0.55. The business has a fifty day moving average of $90.18 and a two-hundred day moving average of $84.75. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The firm had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same period in the previous year, the company earned $1.26 earnings per share. Medtronic’s revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.3%. Medtronic’s dividend payout ratio is currently 70.94%.

Insider Activity at Medtronic

In other news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the sale, the executive vice president directly owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This trade represents a 3.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on MDT. Needham & Company LLC restated a “buy” rating on shares of Medtronic in a research report on Thursday, September 17th. Robert W. Baird boosted their price objective on Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 2nd. Bank of America raised their target price on Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. Truist Financial reaffirmed a “hold” rating and set a $99.00 target price (up from $86.00) on shares of Medtronic in a research note on Wednesday, September 2nd. Finally, Evercore set a $105.00 price target on Medtronic in a research report on Monday, July 6th. Eighteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and a consensus price target of $102.92.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Barclays upgraded MDT to Hold. The move from a less favorable rating removes some analyst pressure on the stock and may support investor sentiment, though a Hold is not an outright bullish recommendation. Medtronic Stock Rating Raised to Hold at Barclays
• Positive Sentiment: Medtronic appointed Felicia Kurz as vice president and general manager of Cardiac Ablation Solutions. The leadership change comes as the company sees strong demand for electrophysiology therapies, particularly its pulsed-field ablation devices. Continued momentum in this business could strengthen Medtronic’s growth outlook. Medtronic names Felicia Kurz as cardiac ablation VP, GM
• Neutral Sentiment: Medtronic announced a final 4.5939 exchange ratio for its MiniMed split-off. The company plans to exchange up to approximately 225.4 million MiniMed Group (NASDAQ: MMED) shares for Medtronic ordinary shares, with the potential to exchange its remaining interest if the offer is oversubscribed. The transaction provides greater clarity on the separation but may also reduce MDT’s share count and ownership of MiniMed. Medtronic Announces Final Exchange Ratio
• Neutral Sentiment: Analyst coverage continues to emphasize MDT’s dividend appeal, with the stock included among healthcare companies offering relatively high yields. That may attract income-focused investors, but the commentary does not introduce a new earnings catalyst. Healthcare stocks with high dividend yields
• Neutral Sentiment: Medtronic’s FY2026 impact report said the company served more than 82 million patients worldwide, reinforcing its scale and healthcare reach but offering limited direct implications for near-term financial results. Medtronic FY2026 Impact Report

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.